Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560585 | 0.91 | FFAR1 (0.63) | CA1CA2CA12CA9POLB | |
| SCHEMBL3553373 | 0.88 | AR (0.62) | CA1CA2CA12CA9POLB | |
| SCHEMBL7501950 | 0.86 | CA1 (0.81) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL3086762 | 0.85 | CA1 (0.66) | CA1CA2CA12CA9POLB | |
| SCHEMBL9320585 | 0.85 | POLB (0.63) | CA1CA2CA12CA9POLB | |
| SCHEMBL14057926 | 0.85 | MAPT (0.74) | CA1CA2CA12CA9POLB | |
| SCHEMBL7932062 | 0.85 | CA12 (0.73) | CA1CA2CA12CA9POLB | |
| SCHEMBL893905 | 0.84 | CA12 (0.73) | CA1CA2CA12CA9POLB | |
| SCHEMBL3715141 | 0.84 | CA12 (0.75) | CA1CA2CA12CA9POLB | |
| SCHEMBL15480542 | 0.84 | HDAC3 (0.69) | CA1CA2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-101490004-B | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMA SPA | 2012-01-11 | — | — | CN | disclosed |
| EP-2044023-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7671066-B2 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-03-02 | — | — | US | disclosed |
| CN-101490004-A | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMA S P A (IT) | 2009-07-22 | — | — | CN | disclosed |
| EP-2044023-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006509-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A.. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | CA1 1353/4885CA2 2183/4885CA12 1212/4885 |
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | CA1 4359/4885CA2 2545/4885CA12 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.